Oliver Eckelmann, Ph.D.

Oliver Eckelmann, Ph.D. has a diverse range of work experience in the biotech, healthcare, and consulting industries. Oliver is the Group CEO and Co-Founder of discoveric bio group, where they focus on the research and development of antibodies for various therapies. Prior to this, they held roles such as Director of the Board of Directors at Medical Templates AG, Director of the Board of Directors and Co-Founder at discovermarket, and COO and CFO at NovImmune. Oliver also co-founded LamKap Bio Group and Entsia, where they held positions as Group COO and CFO and Group CFO, respectively. Additionally, Oliver had extensive experience at Roche, where they held roles such as CFO and Deputy CEO, VP of Global Strategy and Planning, and Group Controller. Oliver also worked as a pharmaceutical industry strategy consultant, serving clients such as Pfizer, Bristol-Myers Squibb, Roche, and Boehringer Ingelheim. Oliver began their career as a Summer Associate at Roland Berger Strategy Consultants. Throughout their career, Oliver has shown strong leadership, strategic planning, and financial management skills.

Oliver Eckelmann, Ph.D. has an extensive education history. In 1998, they started their academic journey at EBS Universität für Wirtschaft und Recht, where they pursued a degree in Business Administration with a focus on Marketing and Entrepreneurship. Oliver successfully completed the program in 2002, earning a Diplom Kauffmann.

Afterwards, in the year 2000, Oliver enrolled at the University of Pittsburgh Katz Graduate School of Business to pursue their MBA. Oliver specialized in Business Administration with a concentration in Corporate Strategy & Finance, and they completed the program in 2001.

Seeking further academic accomplishments, Oliver Eckelmann then joined IMD in 2002 to pursue a Doctor of Philosophy (Ph.D.) in Business Administration, specifically in Strategic Pharma Management. Oliver dedicated three years to their doctoral studies and successfully obtained their Ph.D. in 2005.

In 2008, Oliver returned to IMD to participate in the Roche Executive Leadership Programme - Engage. Furthermore, in 2011, they attended Loroch Communication and Training in Life Science to enhance their knowledge in Molecular Biology for Non-Scientists.

Oliver's thirst for knowledge continued in 2013 when they enrolled in the Duke Corporate Education - Roche Executive Leadership Programme - Catalyst at Duke University - The Fuqua School of Business.

Overall, Oliver Eckelmann, Ph.D. has a diverse and well-rounded education in business administration, with specific expertise in strategic pharma management, corporate strategy, and finance, complemented by additional training in leadership and molecular biology.